Oropharyngeal Squamous Cell Carcinoma Clinical Trials in Los Angeles, California
5 recruitingLos Angeles, California
Showing 1–5 of 5 trials
Recruiting
Phase 2
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Head and Neck Squamous Cell Carcinoma+22 more
National Cancer Institute (NCI)150 enrolled221 locationsNCT05136196
Recruiting
Phase 2Phase 3
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Oropharyngeal p16INK4a-Negative Squamous Cell CarcinomaStage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7+6 more
National Cancer Institute (NCI)613 enrolled341 locationsNCT01810913
Recruiting
Phase 2
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell CarcinomaRecurrent Oropharyngeal Squamous Cell CarcinomaRecurrent Hypopharyngeal Squamous Cell Carcinoma+2 more
National Cancer Institute (NCI)188 enrolled177 locationsNCT04671667
Recruiting
Phase 2
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Locally Recurrent Head and Neck Squamous Cell CarcinomaLocally Recurrent Hypopharyngeal Squamous Cell Carcinoma+15 more
National Cancer Institute (NCI)180 enrolled40 locationsNCT07195734
Recruiting
Phase 2
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Head and Neck Squamous Cell CarcinomaStage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8+38 more
NRG Oncology98 enrolled149 locationsNCT06532279